Jacob Drobnyk Soumerai, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 15 | 2024 | 1640 | 3.940 |
Why?
|
| Lymphoma, Follicular | 5 | 2024 | 457 | 1.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2024 | 11742 | 1.400 |
Why?
|
| Lymphoma, B-Cell | 4 | 2022 | 940 | 1.260 |
Why?
|
| Hyperhidrosis | 2 | 2022 | 34 | 1.010 |
Why?
|
| Lymphoma | 5 | 2023 | 1901 | 0.900 |
Why?
|
| Vincristine | 3 | 2024 | 1036 | 0.870 |
Why?
|
| Sweat | 1 | 2022 | 56 | 0.810 |
Why?
|
| Sulfonamides | 5 | 2024 | 1979 | 0.760 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2024 | 237 | 0.750 |
Why?
|
| Prednisone | 3 | 2024 | 1563 | 0.740 |
Why?
|
| Quinazolinones | 2 | 2019 | 221 | 0.700 |
Why?
|
| Pyrazoles | 4 | 2024 | 2009 | 0.690 |
Why?
|
| Cyclophosphamide | 3 | 2024 | 2220 | 0.680 |
Why?
|
| Waldenstrom Macroglobulinemia | 15 | 2020 | 1073 | 0.670 |
Why?
|
| Doxorubicin | 3 | 2024 | 2224 | 0.640 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2024 | 1405 | 0.620 |
Why?
|
| Purines | 2 | 2019 | 607 | 0.620 |
Why?
|
| Pyrimidines | 4 | 2024 | 3028 | 0.610 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2024 | 1374 | 0.600 |
Why?
|
| Lymphadenitis | 1 | 2019 | 99 | 0.600 |
Why?
|
| Herpesviridae Infections | 1 | 2019 | 270 | 0.580 |
Why?
|
| Mediastinal Neoplasms | 2 | 2016 | 401 | 0.460 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 4544 | 0.410 |
Why?
|
| Agammaglobulinemia | 2 | 2024 | 171 | 0.390 |
Why?
|
| Benzimidazoles | 1 | 2017 | 858 | 0.390 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2024 | 1469 | 0.380 |
Why?
|
| Piperidines | 5 | 2024 | 1656 | 0.370 |
Why?
|
| Fever | 3 | 2022 | 1618 | 0.330 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2023 | 301 | 0.290 |
Why?
|
| Lymph Nodes | 1 | 2019 | 3465 | 0.290 |
Why?
|
| Switzerland | 2 | 2023 | 324 | 0.260 |
Why?
|
| Treatment Outcome | 14 | 2024 | 64685 | 0.250 |
Why?
|
| Aged | 26 | 2024 | 169310 | 0.240 |
Why?
|
| Sweating | 2 | 2022 | 155 | 0.240 |
Why?
|
| Antigens, CD19 | 2 | 2024 | 424 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2019 | 4652 | 0.220 |
Why?
|
| Hypertension | 1 | 2023 | 8540 | 0.220 |
Why?
|
| Middle Aged | 26 | 2024 | 220921 | 0.220 |
Why?
|
| Humans | 50 | 2024 | 761596 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2023 | 5672 | 0.210 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 13642 | 0.210 |
Why?
|
| Drug Administration Schedule | 5 | 2019 | 4853 | 0.210 |
Why?
|
| Models, Biological | 1 | 2018 | 9469 | 0.200 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 58984 | 0.200 |
Why?
|
| Immunization, Passive | 1 | 2024 | 616 | 0.200 |
Why?
|
| Disease-Free Survival | 6 | 2020 | 6815 | 0.200 |
Why?
|
| Mediastinal Diseases | 1 | 2022 | 91 | 0.190 |
Why?
|
| Congresses as Topic | 2 | 2023 | 803 | 0.190 |
Why?
|
| Anthracyclines | 1 | 2023 | 284 | 0.190 |
Why?
|
| Male | 27 | 2024 | 360846 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 9280 | 0.170 |
Why?
|
| Adenine | 3 | 2022 | 987 | 0.170 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 1008 | 0.170 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 629 | 0.170 |
Why?
|
| Adult | 19 | 2024 | 221210 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 6 | 2013 | 694 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2023 | 678 | 0.170 |
Why?
|
| Female | 26 | 2024 | 392705 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 2 | 2022 | 883 | 0.160 |
Why?
|
| Prognosis | 7 | 2023 | 29629 | 0.160 |
Why?
|
| Groin | 1 | 2019 | 106 | 0.160 |
Why?
|
| Central Nervous System | 2 | 2023 | 1336 | 0.160 |
Why?
|
| Nucleosides | 2 | 2009 | 131 | 0.150 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 329 | 0.150 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2019 | 411 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 9 | 2022 | 9177 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 13381 | 0.150 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2018 | 419 | 0.140 |
Why?
|
| Retrospective Studies | 11 | 2024 | 80647 | 0.140 |
Why?
|
| Remission Induction | 2 | 2023 | 2397 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 840 | 0.140 |
Why?
|
| Diarrhea | 1 | 2023 | 1318 | 0.140 |
Why?
|
| Thiazoles | 1 | 2024 | 1517 | 0.140 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2018 | 647 | 0.130 |
Why?
|
| Lung Injury | 1 | 2020 | 422 | 0.130 |
Why?
|
| Simplexvirus | 1 | 2019 | 803 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 916 | 0.120 |
Why?
|
| Interferon Regulatory Factors | 1 | 2016 | 261 | 0.120 |
Why?
|
| Edema | 1 | 2019 | 766 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 857 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 11120 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 1702 | 0.110 |
Why?
|
| Thalidomide | 2 | 2009 | 885 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2019 | 1526 | 0.110 |
Why?
|
| Double-Blind Method | 2 | 2024 | 12341 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 1943 | 0.100 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1869 | 0.090 |
Why?
|
| Vidarabine | 2 | 2008 | 336 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2023 | 2781 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 281 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6484 | 0.080 |
Why?
|
| Survival Rate | 3 | 2020 | 12723 | 0.080 |
Why?
|
| Tunicamycin | 1 | 2008 | 108 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 10766 | 0.080 |
Why?
|
| Plasma Cells | 2 | 2009 | 599 | 0.080 |
Why?
|
| Follow-Up Studies | 7 | 2023 | 39106 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 14608 | 0.070 |
Why?
|
| Genes, Regulator | 1 | 2009 | 373 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2013 | 2643 | 0.070 |
Why?
|
| Biopsy | 1 | 2019 | 6766 | 0.070 |
Why?
|
| Immunoglobulin M | 5 | 2009 | 1526 | 0.070 |
Why?
|
| Hepatitis C Antibodies | 1 | 2007 | 146 | 0.070 |
Why?
|
| Simvastatin | 1 | 2008 | 346 | 0.060 |
Why?
|
| Neutropenia | 3 | 2022 | 885 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 5146 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12463 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 754 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2019 | 7968 | 0.060 |
Why?
|
| Disease Progression | 2 | 2019 | 13510 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12973 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 5305 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2011 | 2203 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 1993 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2020 | 23996 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2008 | 1134 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6484 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 10212 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2008 | 1394 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2022 | 200 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2011 | 4001 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2007 | 1336 | 0.040 |
Why?
|
| Anemia | 1 | 2009 | 1509 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2827 | 0.040 |
Why?
|
| Disease Management | 2 | 2020 | 2508 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 54423 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2009 | 3615 | 0.040 |
Why?
|
| Risk Factors | 3 | 2022 | 74213 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2009 | 4758 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2007 | 2846 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2007 | 1590 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2022 | 664 | 0.040 |
Why?
|
| Young Adult | 4 | 2020 | 59260 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2007 | 1584 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2020 | 10090 | 0.030 |
Why?
|
| Apoptosis | 2 | 2008 | 9490 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 2009 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 2650 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3246 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 2048 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 3826 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 4576 | 0.020 |
Why?
|
| Thrombocytopenia | 2 | 2009 | 1182 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 3879 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1551 | 0.020 |
Why?
|
| Recurrence | 1 | 2022 | 8466 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2023 | 5496 | 0.020 |
Why?
|
| Chlorambucil | 1 | 2008 | 42 | 0.020 |
Why?
|
| Cladribine | 1 | 2008 | 34 | 0.020 |
Why?
|
| Electrophoresis, Capillary | 1 | 2009 | 63 | 0.020 |
Why?
|
| Blood Viscosity | 1 | 2009 | 124 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 1378 | 0.020 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2009 | 101 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8527 | 0.020 |
Why?
|
| Hematocrit | 1 | 2009 | 623 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 2009 | 253 | 0.020 |
Why?
|
| Platelet Count | 1 | 2009 | 781 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2297 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 10194 | 0.020 |
Why?
|
| Gene Expression | 2 | 2009 | 7581 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 615 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 1646 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2008 | 559 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2009 | 915 | 0.020 |
Why?
|
| Protein Folding | 1 | 2008 | 870 | 0.010 |
Why?
|
| Pyrazines | 1 | 2009 | 1202 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2850 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4317 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2008 | 2626 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2008 | 18966 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2008 | 1892 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2009 | 1948 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2008 | 1403 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 1052 | 0.010 |
Why?
|
| Mast Cells | 1 | 2008 | 1392 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2009 | 22176 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8656 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 2457 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 3605 | 0.010 |
Why?
|
| Heart Failure | 1 | 2023 | 11671 | 0.010 |
Why?
|
| Time Factors | 2 | 2011 | 39969 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2008 | 5870 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 4740 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2008 | 2828 | 0.010 |
Why?
|
| Pneumonia | 1 | 2008 | 2143 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41495 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 9353 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 10451 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2009 | 11530 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 21355 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 88326 | 0.000 |
Why?
|
| Animals | 2 | 2008 | 168475 | 0.000 |
Why?
|
| Mice | 1 | 2008 | 81539 | 0.000 |
Why?
|